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Abstract
Background: Hypoglycemia is a vary rare toxicity of rituximab. The exact mechanism of rituximab
induced hypoglycemia is not clear.
Case presentation: A 50 year old female presented with a left tonsillar non Hodgkin's lymphoma
and was started on R-CHOP chemotherapy. Twenty four hours after the first rituximab infusion,
she developed hypoglycemia which was managed by IV glucose infusion.
Conclusion:  Hypoglycemia following rituximab administration is rare. Possibilities of
hypoglycemia should be kept in mind in patients developing symptoms like fatigue, restlessness, and
sweating while on rituximab therapy.
Background
Hypoglycemia is a rare complication of rituximab treat-
ment. The exact cause of this phenomenon is not known.
We report here a case of non-Hodgkin's lymphoma devel-
opin hypoglycemia on being treated with R-CHOP chem-
otherapy
Case presentation
A 50-year-old female presented in January 2004 with a 4
cm left tonsillar mass. Her general and systemic examina-
tions were unremarkable. There was no lymphadenopa-
thy or hepato-splenomegaly. Her hemoglobin was 12.5
gm/dl, white blood cell (WBC) count was 7700/mm3,
erythrocyte sedimentation rate (ESR) was 50 mm/hour
and random blood sugar (RBS) was 96 mg/dl. Renal and
liver function tests were normal. VDRL, HIV and HBsAg
were non-reactive. Chest X-ray, ultrasound scan of the
abdomen, upper gastro-intestinal endoscopy, peripheral
blood smear and bone marrow biopsy were normal. There
was no past history of diabetes mellitus, hypo or hyperg-
lycemic episodes. Biopsy and histopathological examina-
tion of the tonsillar mass was consistent with Non
Hodgkin's lymphoma-diffuse large B cell type. Immuno-
histochemistry showed the tumor cells to be CD20 posi-
tive. She was treated using R-CHOP (rituximab 375 mg/
m2 + cyclophosphamide 750 mg/m2 + doxorubicin 50
mg/m2 + vincristine 1.4 mg/m2 + prednisolone 100 mg
orally) chemotherapy on a three weekly schedule after
obtaining informed consent. About 24 hours following
rituximab, she developed hypoglycemic symptoms like
fatigue, restlessness, sweating and drowsiness. There was
no other rituximab infusion related toxicities. Her RBS at
that time was 39 mg/dl. Her symptoms subsided follow-
ing intravenous (IV) glucose administration and RBS
became normal. During the next 48 hours, she developed
three more symptomatic hypoglycemic episodes, with
RBS nadir 54 mg/dl, 61 mg/dl and 70 mg/dl respectively
and were managed with IV glucose administration. Three
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days after rituximab her hypoglycemic symptoms sub-
sided completely and the RBS improved to normal range.
During the subsequent courses of rituximab, she was
given IV glucose support during the first 72 hours. There
were no further episodes of symptomatic hypoglycemia.
Discussion
Rituximab is a chimeric murine/human monoclonal anti-
body directed against CD-20 positive cells. Commonly
observed toxicities are fever(55%), chills(33%), asthe-
nia(25%), lymphopenia (48%), nausea (23%), bronchos-
pasm (10%), anemia (15%), neutropenia (15%),
abdominal pain (14%), back pain (10%), flushing (5%),
angio-edema (11%), peripheral edema (8%), night sweats
(15%) hypotension (10%) and hypertension (6%). Meta-
bolic complications like hyperkalemia, hyperuricemia,
hyperphosphatemia and hypocalcemia have been
observed 12–24 hours after an infusion due to an associ-
ation with a reduction in tumor burden. Rarely hypergly-
cemia is also seen [1,2]. But occurrence of hypoglycemia
is vary rare and is reported in more than 1 but less than
5% of patients. The exact mechanism of rituximab
induced hypoglycemia is not clear [2]. Rituximab has also
been used to treat type B syndrome of severe insulin resist-
ance in one patient earlier [3].
Conclusion
Even though its occurrence is rare, the possibility of
hypoglymia should always be kept in mind.
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